
TY  - JOUR
TI  - Abstracts
JO  - BJU International
VL  - 87
IS  - s1
SN  - 1464-4096
UR  - https://doi.org/10.1046/j.1464-410X.87.s1.2.x
DO  - doi:10.1046/j.1464-410X.87.s1.2.x
SP  - 1
EP  - 77
PY  - 2001
ER  - 

TY  - JOUR
TI  - French-English-German
JO  - Journal of Cardiovascular Electrophysiology
JA  - Mack/Dictionary
VL  - 20
IS  - s1
SN  - 1045-3873
UR  - https://doi.org/10.1111/j.1540-8167.2009.01586.x
DO  - doi:10.1111/j.1540-8167.2009.01586.x
SP  - S1
EP  - S59
PY  - 2009
AB  - Summary This chapter contains sections titled: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ER  - 

C7  - pp. 1051-1518
TI  - INDEX TO VOLUME 2, 1970
SN  - 9783826334054
UR  - https://doi.org/10.1002/9780470760338.ch3
DO  - doi:10.1002/9780470760338.ch3
SP  - 1051-1518
PY  - 2009
ER  - 

TY  - JOUR
TI  - Summaries of Posters
JO  - Medical Journal of Australia
VL  - 2
IS  - 1
SN  - 9783826334054
UR  - https://doi.org/10.5694/j.1326-5377.1970.tb84661.x
DO  - doi:10.5694/j.1326-5377.1970.tb84661.x
SP  - iii
EP  - xxv
PY  - 1970
ER  - 

TY  - JOUR
TI  - Ischaemic Case Studies
JO  - British Journal of Dermatology
JA  - Foster/Diabetic Foot Care
VL  - 141
IS  - S55
SN  - 9783826334054
UR  - https://doi.org/10.1111/bjd.1999.141.s55.43
DO  - doi:10.1111/bjd.1999.141.s55.43
SP  - 43
EP  - 88
KW  - Ischaemic Case Studies
KW  - vacuum assisted closure (VAC)
KW  - heparin induced thrombocytopenia thrombosis syndrome (HITTS)
KW  - Infection and its presentations
KW  - Patients with severe co-morbidities
KW  - Pain in the neuroischaemic foot
KW  - Conservative care
PY  - 1999
AB  - Summary This chapter contains sections titled: Introduction Infection and its presentations Patients with severe co-morbidities Revascularisation Wound care Emboli Complications Pain in the neuroischaemic foot Conservative care
ER  - 

C7  - pp. 83-155
TI  - Posters
SN  - 9780470998236
UR  - https://doi.org/10.1002/9780470682944.ch2
DO  - doi:10.1002/9780470682944.ch2
SP  - 83-155
PY  - 1999
ER  - 

TY  - JOUR
TI  - Posters – Implant Therapy Outcomes, Surgical Aspects
JO  - Colorectal Disease
JA  - Clin. Oral Impl. Res.
VL  - 13
IS  - s6
SN  - 9780470998236
UR  - https://doi.org/10.1111/j.1463-1318.2011.02707.x
DO  - doi:10.1111/j.1463-1318.2011.02707.x
SP  - 28
EP  - 62
PY  - 2011
ER  - 

TY  - JOUR
TI  - INTERNATIONAL SOCIETY FOR BIOMEDICAL RESEARCH ON ALCOHOLISM
JO  - Clinical Oral Implants Research
VL  - 24
IS  - s9
SN  - 9780470998236
UR  - https://doi.org/10.1111/clr.12249
DO  - doi:10.1111/clr.12249
SP  - 103
EP  - 154
PY  - 2013
ER  - 

TY  - JOUR
AU  - Robson, Martin C.
AU  - Cooper, Diane M.
AU  - Aslam, Rummana
AU  - Gould, Lisa J.
AU  - Harding, Keith G.
AU  - Margolis, David J.
AU  - Ochs, Diane E.
AU  - Serena, Thomas E.
AU  - Snyder, Robert J.
AU  - Steed, David L.
AU  - Thomas, David R.
AU  - Wiersma-Bryant, Laurel
TI  - Guidelines for the treatment of venous ulcers
JO  - Alcoholism: Clinical and Experimental Research
VL  - 16
IS  - 3
SN  - 9780470998236
UR  - https://doi.org/10.1111/j.1530-0277.1992.tb01424.x
DO  - doi:10.1111/j.1530-0277.1992.tb01424.x
SP  - 600
EP  - 656
PY  - 1992
ER  - 

TY  - JOUR
TI  - ASBMR-IBMS second joint meeting
JO  - Wound Repair and Regeneration
JA  - J Bone Miner Res
VL  - 14
IS  - 6
SN  - 9780470998236
UR  - https://doi.org/10.1111/j.1524-475X.2006.00174.x
DO  - doi:10.1111/j.1524-475X.2006.00174.x
SP  - 649
EP  - 662
PY  - 2006
ER  - 

TY  - JOUR
TI  - American Society for Laser Medicine and Surgery fifteenth annual meeting San Diego, California April 2-4, 1995 abstracts
JO  - Journal of Bone and Mineral Research
JA  - Lasers Surg. Med.
VL  - 13
IS  - S1
SN  - 9780470998236
UR  - https://doi.org/10.1002/jbmr.5650130102
DO  - doi:10.1002/jbmr.5650130102
SP  - S1
EP  - S653
PY  - 1998
ER  - 

TY  - JOUR
TI  - Free Papers
JO  - Lasers in Surgery and Medicine
VL  - 17
IS  - S7
SN  - 9780470998236
UR  - https://doi.org/10.1002/lsm.1900170502
DO  - doi:10.1002/lsm.1900170502
SP  - 1
EP  - 82
PY  - 1995
ER  - 

TY  - JOUR
TI  - Antibody engineering: Research and application of genes encoding immunoglobulins
JO  - Artificial Organs
JA  - J. Cell. Biochem.
VL  - 19
IS  - 10
SN  - 9780470998236
UR  - https://doi.org/10.1111/j.1525-1594.1995.tb02266.x
DO  - doi:10.1111/j.1525-1594.1995.tb02266.x
SP  - 1036
EP  - 1071
PY  - 1995
ER  - 

TY  - JOUR
TI  - XXIst International Pigment Cell Conference (IPCC)
JO  - Journal of Cellular Biochemistry
VL  - 56
IS  - S18D
SN  - 9780470998236
UR  - https://doi.org/10.1002/jcb.240560806
DO  - doi:10.1002/jcb.240560806
SP  - 179
EP  - 217
PY  - 1994
ER  - 

TY  - JOUR
AU  - Omar, Kawa
AU  - Khan, Nawal Shamim
AU  - Khan, Muhammad Shamim
TI  - Bladder Neoplasm
JO  - Pigment Cell & Melanoma Research
VL  - 24
IS  - 4
SN  - 9780470998236
UR  - https://doi.org/10.1111/j.1755-148X.2011.00885.x
DO  - doi:10.1111/j.1755-148X.2011.00885.x
SP  - 742
EP  - 863
KW  - bladder cancer
KW  - transitional cell carcinoma
KW  - non-muscle–invasive bladder cancer
KW  - muscle-invasive carcinoma
KW  - diagnosis and management of bladder cancer
PY  - 2011
AB  - Summary Bladder cancer is the most common urothelial malignancy. More than 90% arise from the transitional cell lining of the urinary tract. The remainder of the histological variants include squamous cell cancer, adeno carcinoma, and other rare tumours. Urothelial cancer is associated with smoking and exposure to industrial carcinogens. This cancer generally affects people who are older and who have many comorbidities, which makes their management more challenging. More than two-thirds of the urothelial cancers are non-muscle?invasive bladder cancer (NMIBC) confined to the mucosa or submucosal layers of the bladder wall and remainder are muscle-invasive bladder cancer (MIBC). NMIBC have tendency to recur, and the risk of recurrence varies between 15 and 80% and the majority of the recurrences occur within 6?12?months. Hence, intensive surveillance with cystoscopy and imaging of the urinary tract is required, which in turn incurs a high cost to the healthcare systems. The NMIBC cancers are classified based on their risk of recurrence and progression into low, intermediate, and high risk to tailor subsequent management and surveillance. In addition to the initial transurethral resection, intravesical therapies in the form of chemotherapy, immunotherapy, or a combination are used to reduce recurrence or progression of the disease. For MIBC or high-risk NMIBC, radical cystectomy and urinary diversion is the mainstay of treatment. Radical cystectomy is a life-changing operation and is associated with significant perioperative morbidity and mortality. Therefore, experts in the field are striving to minimise the morbidity of the procedure by using minimal invasive techniques of laparoscopy or robotic surgery in combination with enhanced recovery pathways to expedite recovery. There remains a risk of recurrence even after radical cystectomy due to micrometastasis. Various chemotherapy regimens have been used to decrease this in the neoadjuvant and adjuvant settings. Neoadjuvant chemotherapy has so far provided 5?8% absolute survival benefit at the expense of significant morbidity. In patients unfit or unwilling to undergo radical cystectomy, bladder preservation is an alternative which includes external beam radiotherapy and chemotherapy after transurethral resection. There is not enough evidence to prove the equivalence of this to radical surgery. In those with advanced or metastatic disease, patients are put on palliative care pathway because the natural history of the disease is poor with four to six?months expected survival. However, some newer immuno-therapies that inhibit the interaction between programmed death ligand 1 (PD-L1), present on the surface of tumour or antigen-presenting cells, and programmed death 1 (PD-1), present on the surface of activated lymphocytes, are offering new hope to the patients with advanced disease. In some cases of locally advanced cancer, palliative cystectomy can be performed for control of recurrent bleeding.
ER  - 

AU  - Caers, Jo
AU  - Vande broek, Isabelle
AU  - De Raeve, Hendrik
AU  - Michaux, Lucienne
AU  - Trullemans, Fabienne
AU  - Schots, Rik
AU  - Van Camp, Ben
AU  - Vanderkerken, Karin
C7  - pp. 409-446
TI  - Multiple myeloma – an update on diagnosis and treatment
SN  - 9781118863374
UR  - https://doi.org/10.1002/9781118863343.ch21
DO  - doi:10.1002/9781118863343.ch21
SP  - 409-446
KW  - multiple myeloma
KW  - management
KW  - risk stratification
PY  - 2011
AB  - Abstract Multiple myeloma is a plasma cell (PC) malignancy characterized by the accumulation of monoclonal PCs in the bone marrow and the production of large amounts of a monoclonal immunoglobulin or paraprotein. In the past years, new approaches in the diagnosis and treatment were introduced aiming to identify high-risk patients who need proper anti-myeloma treatment. Intensive therapy including autologous hematopoietic stem cell transplantation and the new agents bortezomib, thalidomide, and lenalidomide have improved patients? responses. Further optimalization of the different treatment schedules in well-defined patient groups may prolong their survival. Patient stratification is currently based on patient characteristics, extent of myeloma disease, and associated cytogenetic and laboratory anomalies. More and more gene expression studies are introduced to stratify patients and to individualize therapy.
ER  - 

TY  - JOUR
TI  - Oral Abstracts
JO  - European Journal of Haematology
JA  - J Clin Periodontol
VL  - 81
IS  - 5
SN  - 9781118863374
UR  - https://doi.org/10.1111/j.1600-0609.2008.01127.x
DO  - doi:10.1111/j.1600-0609.2008.01127.x
SP  - 329
EP  - 343
PY  - 2008
ER  - 

TY  - JOUR
TI  - Posters
JO  - Journal of Clinical Periodontology
VL  - 39
IS  - s13
SN  - 9781118863374
UR  - https://doi.org/10.1111/j.1600-051x-2012.01890_1.x
DO  - doi:10.1111/j.1600-051x-2012.01890_1.x
SP  - 1
EP  - 75
PY  - 2012
ER  - 

TY  - JOUR
AU  - Tang, Lisa
AU  - Meibohm, Bernd
TI  - Pharmacokinetics of Peptides and Proteins
JO  - Diabetic Medicine
JA  - MEIBOHM:PHARMACOKINETICS O‐BK
VL  - 23
IS  - s4
SN  - 9781118863374
UR  - https://doi.org/10.1111/j.1464-5491.2006.02037_13.x
DO  - doi:10.1111/j.1464-5491.2006.02037_13.x
SP  - 265
EP  - 410
KW  - pharmacokinetics
KW  - pharmacodynamics
KW  - biotech drugs
KW  - peptides and proteins
KW  - administration pathways
KW  - administration route
KW  - immunogenicity
KW  - distribution
KW  - elimination
KW  - interspecies scaling
PY  - 2006
AB  - Summary This chapter contains sections titled: Introduction Administration Pathways Administration by Injection or Infusion Inhalational Administration Intranasal Administration Transdermal Administration Peroral Administration Administration Route and Immunogenicity Distribution Elimination Proteolysis Gastrointestinal Elimination Renal Elimination Hepatic Elimination Receptor-Mediated Endocytosis Interspecies Scaling Conclusions References
ER  - 

C7  - pp. 15-43
TI  - Pharmacokinetics of Peptides and Proteins
SN  - 9783527314089
UR  - https://doi.org/10.1002/9783527609628.ch2
DO  - doi:10.1002/9783527609628.ch2
SP  - 15-43
PY  - 2006
ER  - 
